文章：

基于PSMA的放射性配体疗法在前列腺癌治疗中日益重要的作用综述

Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer

原文发布日期：12 July 2024

DOI: 10.3390/cancers16142520

类型: Article

开放获取: 是

英文摘要：

In 2021, two randomized controlled trials (RCTs), TheraP and VISION, demonstrated that177Lu-PSMA-617 as monotherapy was more effective for the decline of PSA than the comparator third-line treatments. Methods: Our review summarizes new RCTs that add to the use of radioligand therapy (RLT) for patients with high-risk prostate cancer (PCa). Results: Four past and present RCTs included 1081 patients. An RCT, ENZA-p, studied first-line treatment of patients with metastatic castration-resistant PCa (mCRPC). A combination of enzalutamide (ENZA) and177Lu-PSMA-617 gave longer progression-free survival than ENZA as monotherapy. Other RCTs of patients with mCRPC, including the PSMAfore, and SPLASH trials, showed177Lu-PSMA-617 as second-line treatment gave better progression-free survival than androgen receptor pathway inhibitors (combinedpvalue < 6.9 × 10−6). Conclusions: Patients with PCa gain if they are given PSMA-RLT early in the treatment of PCa and as part of combination therapies.

摘要翻译： 

2021年，两项随机对照试验（TheraP与VISION）证实，作为单一疗法的177Lu-PSMA-617在降低前列腺特异性抗原（PSA）方面优于对照组的第三线治疗方案。方法：本综述总结了关于放射性配体疗法（RLT）在高危前列腺癌（PCa）患者中应用的最新随机对照试验。结果：四项既往及当前的随机对照试验共纳入1081例患者。其中ENZA-p试验研究了转移性去势抵抗性前列腺癌（mCRPC）患者的一线治疗方案，结果显示恩扎卢胺（ENZA）联合177Lu-PSMA-617治疗比单用ENZA能显著延长无进展生存期。其他针对mCRPC患者的随机对照试验（包括PSMAfore和SPLASH试验）表明，作为二线治疗的177Lu-PSMA-617相较于雄激素受体通路抑制剂能显著改善无进展生存期（合并p值<6.9×10−6）。结论：在前列腺癌治疗早期阶段采用PSMA靶向放射性配体疗法，并将其纳入联合治疗方案，可使前列腺癌患者获益。

原文链接：

Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer